Search research articles
Contact Us
Filters
Showing results (91-100 of 164) with videos related to
Page
of 17
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
December 27, 2017
Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes
Jonathan E Brammer, Dai Chihara, L Michelle Poon, et al.
Cancer Science
|
July 24, 2012
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan
Yasuhiro Oki, Yutaka Kondo, Kazuhito Yamamoto, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 3, 2017
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP
Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, et al.
British Journal of Haematology
|
July 22, 2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
Jason R Westin, Peter McLaughlin, Jorge Romaguera, et al.
Genome Research
|
August 19, 2010
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer
Marcos R H Estécio, Juan Gallegos, Céline Vallot, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 19, 2019
Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides
Yi An, Wen Jiang, Therese Y Andraos, et al.
Cancers
|
August 23, 2020
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen, Bradley M Haverkos, Jasmine Zain, et al.
The Lancet. Oncology
|
April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes, Jesus G Berdeja, Manish R Patel, et al.
Haematologica
|
May 11, 2019
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
Paolo Strati, Loretta J Nastoupil, Richard E Davis, et al.
Leukemia & Lymphoma
|
April 5, 2018
Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy
Chelsea C Pinnix, Andrew Wirth, Sarah A Milgrom, et al.
Page
of 17
Search research articles
Search
Showing results (91-100 of 164) with videos related to
Sort By:
Page
of 17
Clinical Lymphoma, Myeloma & Leukemia
|
December 27, 2017
Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes
Jonathan E Brammer, Dai Chihara, L Michelle Poon, et al.
Cancer Science
|
July 24, 2012
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan
Yasuhiro Oki, Yutaka Kondo, Kazuhito Yamamoto, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 3, 2017
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP
Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, et al.
British Journal of Haematology
|
July 22, 2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
Jason R Westin, Peter McLaughlin, Jorge Romaguera, et al.
Genome Research
|
August 19, 2010
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer
Marcos R H Estécio, Juan Gallegos, Céline Vallot, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 19, 2019
Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides
Yi An, Wen Jiang, Therese Y Andraos, et al.
Cancers
|
August 23, 2020
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen, Bradley M Haverkos, Jasmine Zain, et al.
The Lancet. Oncology
|
April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes, Jesus G Berdeja, Manish R Patel, et al.
Haematologica
|
May 11, 2019
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
Paolo Strati, Loretta J Nastoupil, Richard E Davis, et al.
Leukemia & Lymphoma
|
April 5, 2018
Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy
Chelsea C Pinnix, Andrew Wirth, Sarah A Milgrom, et al.
Page
of 17